US4845115A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of medical treatment
Assignee: Glaxo Group Ltd
•
Filing: 1987-12-16
•
Granted: 1989-07-04
•
Expires: 2007-12-16
Abstract
Abstract The invention relates to the use of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one and physiologically acceptable salts and solvates thereof in the treatment of cognitive disorders such as attentional and memory deficits and dementia states.
Inventors
- 👤 Michael B. Tyers
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 20:40
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/41; A61K31/415; A61P; A61P25/00; A61P25/28; A61P43/00
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
49 words
A method for treatment of dementia and other cognitive disorders which comprises administering to a human or animal subject suffering from dementia or other cognitive disorders an effective amount for the treatment of said dementia or other cognitive disorders of 1,2,3,9,-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one or a physiologically acceptable salt or solvate thereof.
Claim 2
Independent Claim
49 words
A method for treatment of dementia and other cognitive disorders which comprises administering to a human or animal subject suffering from dementia or other cognitive disorders an effective amount for the treatment of said dementia or other cognitive disorders of 1,2,3,9,-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one or a physiologically acceptable salt or solvate thereof.
Claim 3
Dependent Claim
18 words
A method according to claim 1 wherein said 1,2,3,9,-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one is administered in the form of a hydrochloride salt.
Claim 4
Dependent Claim
19 words
A method according to claim 1 wherein said 1,2,3,9,-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one is administered in the form of the hydrochloride dihydrate salt.
Claim 5
Dependent Claim
45 words
A method according to claim 1 wherein said 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one or a physiologically acceptable salt or solvate thereof is administered in a dose of 0.5 μg to 20 mg from 1 to 4 times per day, the dose being expressed as the weight of free base.
Claim 6
Dependent Claim
45 words
A method according to claim 1 wherein said 1,2,3,9-tetrahydro-9-methyl-3-[)2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one or a physiologically acceptable salt or solvate thereof is administered in a dose of 0.05 mg to 20 mg from 1 to 4 times per day, the dose being expressed as the weight of free base.
Claim 7
Dependent Claim
20 words
A method according to claim 1 wherein said 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one is administered orally, buccally, parenterally, rectally, or as a depot preparation.
References Cited (Backward Citations)
GB2153821A
Cited
EP0190920A2
Cited
US4721720A
Cited
US4721720B1
Cited
US4624961A
Cited
US4753789A
Cited
GB2193633A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-07-03 | 1993-01-02 | 1993-07-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-07-03 | 1997-01-02 | 1997-07-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-07-03 | 2001-01-02 | 2001-07-04 | $7700.00 | Window Closed / Lapsed |